|
1
|
Coca-Pelaz A, Rodrigo JP, Bradley PJ,
Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A,
Haigentz M Jr, Takes RP, et al: Adenoid cystic carcinoma of the
head and neck-An update. Oral Oncol. 51:652–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duarte AF, Alpuim Costa D, Cacador N,
Boavida AM, Afonso AM, Vilares M and Devoto M: Adenoid cystic
carcinoma of the palpebral lobe of the lacrimal gland-case report
and literature review. Orbit. 41:605–610. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gou WB, Yang YQ, Song BW and He P: Solid
basal adenoid cystic carcinoma of the breast: A case report and
literature review. Medicine (Baltimore). 103:e370102024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee TH, Kim K, Oh D, Yang K, Jeong HS,
Chung MK and Ahn YC: Clinical outcomes in adenoid cystic carcinoma
of the nasal cavity and paranasal sinus: A comparative analysis of
treatment modalities. Cancers (Basel). 16:12352024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gural Z, Yucel S and Agaoglu F:
Bartholin's gland adenoid cystic carcinoma: Report of three cases
and the review of literature. Indian J Cancer. 61:346–349. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schembri-Wismayer D, Gupta S and Erickson
LA: Cutaneous adenoid cystic carcinoma. Mayo Clin Proc.
99:1017–1018. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baker GM, Selim MA and Hoang MP: Vulvar
adnexal lesions: A 32-year, single-institution review from
Massachusetts General Hospital. Arch Pathol Lab Med. 137:1237–1246.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Atallah S, Casiraghi O, Fakhry N, Wassef
M, Uro-Coste E, Espitalier F, Sudaka A, Kaminsky MC, Dakpe S, Digue
L, et al: A prospective multicentre REFCOR study of 470 cases of
head and neck Adenoid cystic carcinoma: Epidemiology and prognostic
factors. Eur J Cancer. 130:241–249. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Morais EF, da Silva LP, Moreira DGL,
Mafra RP, Rolim LSA, de Moura Santos E, de Souza LB and de Almeida
Freitas R: Prognostic factors and survival in adenoid cystic
carcinoma of the head and neck: A retrospective clinical and
histopathological analysis of patients seen at a cancer center.
Head Neck Pathol. 15:416–424. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dodd RL and Slevin NJ: Salivary gland
adenoid cystic carcinoma: A review of chemotherapy and molecular
therapies. Oral Oncol. 42:759–769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ellington CL, Goodman M, Kono SA, Grist W,
Wadsworth T, Chen AY, Owonikoko T, Ramalingam S, Shin DM, Khuri FR,
et al: Adenoid cystic carcinoma of the head and neck: Incidence and
survival trends based on 1973–2007 surveillance, epidemiology, and
end results data. Cancer. 118:4444–4451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nabetani A, Koujin T, Tsutsumi C,
Haraguchi T and Hiraoka Y: A conserved protein, Nuf2, is implicated
in connecting the centromere to the spindle during chromosome
segregation: A link between the kinetochore function and the
spindle checkpoint. Chromosoma. 110:322–334. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie X, Jiang S and Li X: Nuf2 is a
prognostic-related biomarker and correlated with immune infiltrates
in hepatocellular carcinoma. Front Oncol. 11:6213732021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Wang Y, Wang J, Jiang W, Chen Y,
Shan J, Li X and Wu X: NUF2 regulated the progression of
hepatocellular carcinoma through modulating the PI3K/AKT pathway
via stabilizing ERBB3. Transl Oncol. 44:1019332024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng B, Wang S, Yuan X, Zhang J, Shen Z
and Ge C: NUF2 is correlated with a poor prognosis and immune
infiltration in clear cell renal cell carcinoma. BMC Urol.
23:822023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu X, Zou Y, Wu T, Ni J, Tan Q, Wang Q
and Zhang M: ANP32E contributes to gastric cancer progression via
NUF2 upregulation. Mol Med Rep. 26:2752022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhai X, Yang Z, Liu X, Dong Z and Zhou D:
Identification of NUF2 and FAM83D as potential biomarkers in
triple-negative breast cancer. PeerJ. 8:e99752020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang F, Huang X, Yang X, Zhou H and Wang
Y: NUF2 expression promotes lung adenocarcinoma progression and is
associated with poor prognosis. Front Oncol. 12:7959712022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lv S, Xu W, Zhang Y, Zhang J and Dong X:
NUF2 as an anticancer therapeutic target and prognostic factor in
breast cancer. Int J Oncol. 57:1358–1367. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren M, Zhao H, Gao Y, Chen Q, Zhao X and
Yue W: NUF2 promotes tumorigenesis by interacting with HNRNPA2B1
via PI3K/AKT/mTOR pathway in ovarian cancer. J Ovarian Res.
16:172023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuce Sari S, Yazici G, Elmali A, Bayatfard
P, Koc I, Kiratli H and Cengiz M: Radiotherapy for adenoid cystic
carcinoma of the lacrimal gland: Study on twelve patients. Cancer
Radiother. 29:1046442025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Andersson MK, Afshari MK, Andren Y, Wick
MJ and Stenman G: Targeting the oncogenic transcriptional regulator
MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT
signaling. J Natl Cancer Inst. 109:djx0172017. View Article : Google Scholar
|
|
23
|
Persson M, Andersson MK, Sahlin PE, Mitani
Y, Brandwein-Weber MS, Frierson HF Jr, Moskaluk C, Fonseca I,
Ferrarotto R, Boecker W, et al: Comprehensive molecular
characterization of adenoid cystic carcinoma reveals tumor
suppressors as novel drivers and prognostic biomarkers. J Pathol.
261:256–268. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hochberg Y and Hochberg Y: Controlling the
false discovery rate a practical and powerful approach to multiple
testing. J Royal Stat Soc Series B. 57:289–300. 1995. View Article : Google Scholar
|
|
25
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res. 48:W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hutter C and Zenklusen JC: The cancer
genome atlas: Creating lasting value beyond its data. Cell.
173:283–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin J, Chen X, Yu H, Min S, Chen Y, Li Z
and Xie X: NUF2 drives clear cell renal cell carcinoma by
activating HMGA2 transcription through KDM2A-mediated H3K36me2
demethylation. Int J Biol Sci. 18:3621–3635. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stawarz K, Durzynska M, Galazka A,
Gorzelnik A, Zwolinski J, Paszkowska M, Bieńkowska-Pluta K and
Misiak-Galazka M: Current landscape and future directions of
therapeutic approaches for adenoid cystic carcinoma of the salivary
glands (Review). Oncol Lett. 29:1532025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Chen L, Luo Y, Shen J and Zhou S:
Predictive value of NUF2 for prognosis and immunotherapy responses
in pan-cancer. Nan Fang Yi Ke Da Xue Xue Bao. 45:137–149. 2025.(In
Chinese). PubMed/NCBI
|
|
31
|
Zhang S, Zhang L, Cai L, Chen H, Wang Y,
Yuan Y, Zhang H and Wei X: NUF2 overexpression predicts poor
outcomes in multiple myeloma. Genes Dis. 12:1012682025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Q, Dai SJ, Li H, Dong L and Peng YP:
Silencing of NUF2 inhibits tumor growth and induces apoptosis in
human hepatocellular carcinomas. Asian Pac J Cancer Prev.
15:8623–8629. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Elhanani O, Ben-Uri R and Keren L: Spatial
profiling technologies illuminate the tumor microenvironment.
Cancer Cell. 41:404–420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rodrigo JP, Sanchez-Canteli M, Lopez F,
Wolf GT, Hernández-Prera JC, Williams MD, Willems SM, Franchi A,
Coca-Pelaz A and Ferlito A: Tumor-infiltrating lymphocytes in the
tumor microenvironment of laryngeal squamous cell carcinoma:
Systematic review and meta-analysis. Biomedicines. 9:4862021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Affo S, Yu LX and Schwabe RF: The role of
cancer-associated fibroblasts and fibrosis in liver cancer. Annu
Rev Pathol. 12:153–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu Q, Hu J, Wang Y and Wang Z: The role of
tumor types in immune-related adverse events. Clin Transl Oncol.
27:3247–3260. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Garg P, Pareek S, Kulkarni P, Horne D,
Salgia R and Singhal SS: Next-Generation immunotherapy: Advancing
clinical applications in cancer treatment. J Clin Med. 13:65372024.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu B, Zhou H, Tan L, Siu KTH and Guan XY:
Exploring treatment options in cancer: Tumor treatment strategies.
Signal Transduct Target Ther. 9:1752024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Waldman AD, Fritz JM and Lenardo MJ: A
guide to cancer immunotherapy: From T cell basic science to
clinical practice. Nat Rev Immunol. 20:651–668. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wolkow N, Jakobiec FA, Afrogheh AH, Kidd
M, Eagle RC, Pai SI and Faquin WC: PD-L1 and PD-L2 expression
levels are low in primary and secondary adenoid cystic carcinomas
of the orbit: Therapeutic implications. Ophthalmic Plast Reconstr
Surg. 36:444–450. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mosconi C, de Arruda JAA, de Farias ACR,
Oliveira GAQ, de Paula HM, Fonseca FP, Mesquita RA, Silva TA,
Mendonça EF and Batista AC: Immune microenvironment and evasion
mechanisms in adenoid cystic carcinomas of salivary glands. Oral
Oncol. 88:95–101. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sato R, Yamaki H, Komatsuda H, Wakisaka R,
Inoue T, Kumai T and Takahara M: Exploring immunological effects
and novel immune adjuvants in immunotherapy for salivary gland
cancers. Cancers (Basel). 16:12052024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li X, Zhang L, Yi Z, Zhou J, Song W, Zhao
P, Wu J, Song J and Ni Q: NUF2 is a potential immunological and
prognostic marker for non-small-cell lung cancer. J Immunol Res.
2022:11619312022.PubMed/NCBI
|
|
47
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
